Expanding the labeled indication to include OSA opened the door to payer-supported access to GLP-1 therapy for patients with obesity-associated OSA, with the potential to reduce reliance on devices
24-Hour Processing Orders placed before 12pm GMT ship the same day from our UK hub
Adriane Fugh-Berman explains how visuals in ads and cherry-picked safety disclosures are among the deceptive tactics that have been used for years to promote drugs directly to consumers
Mechanistically, even small stimulation of GLP-1 receptors can: Reduce hunger and cravings, making it easier to stick to a reduced-calorie eating pattern Smooth out blood sugar spikes after meals, which may reduce energy crashes and rebound hunger Support improvements in weight-related markers such as HbA1c, especially when combined with lifestyle changes However, it is important to be clear about the evidence
Prior to taking up this position, Lim had published a number of papers in 1923 on the structure and function of the stomach, including the effect of gastrin and secretin on gastro-duodenal secretions
That status matters because labs are already looking for patterns of use and if evidence of abuse emerges GLP1 drugs could shift from watched to prohibited in a future Prohibited List update
